FDA Approvals, Discontinuations, and Health Developments: Latest Updates

This summary highlights key updates in the health sector, including FDA approvals for therapies for blood cancer and allergic reactions, Merck's discontinued lung cancer drug trial, Perrigo's infant formula recall, widespread skin diseases among Gaza's children, and bluetongue vaccination in France. It also covers developments in vape-like devices for migraines and asthma, Canopy Growth's financial report, a new swine flu case in Michigan, and the FDA's extended review of Humacyte's blood vessel implant.

The health sector witnessed significant developments this week, as the U.S. Food and Drug Administration approved new therapies, including a treatment for rare blood cancer developed by Citius Pharmaceuticals, and a nasal spray alternative to EpiPen for allergic reactions by ARS Pharmaceuticals. The FDA also extended its review of Humacyte's blood vessel implant.

Meanwhile, Merck has halted a lung cancer drug trial due to inefficacy and higher immune-related side effects. Perrigo recalled 16,500 cans of infant formula over safety concerns. Additionally, the ongoing conflict in Gaza has led to severe skin diseases among children due to harsh living conditions.

France is ramping up its bluetongue vaccination campaign after detecting new outbreaks. On the innovation front, companies like Qnovia and MIIST Therapeutics are developing vape-like devices for migraines and asthma. In financial news, Canopy Growth reported a smaller-than-expected core loss, and Michigan identified a new human case of swine flu.

(With inputs from agencies.)